AbCellera Biologics Inc. Insider Trading

ABCL

Cluster buy

3 insiders bought $1.55M of their own stock in 13 days.

Open-market purchases by executives and directors between Aug 12 and Aug 24. Buying is rarer than selling and says more, but it is one input, not a verdict.

Net open-market

+$1.97M

7 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

3 / 0

executives and directors

Last open-market buy

Aug 2026

Aug 24, 2026

Get an email when ABCL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 24	Michael R Hayden Director	Bought	53,613	$10.64	570K	3.7%	Form 4
Aug 18	John S. Montalbano Director	Bought	10,000	$11.03	110K	4.1%	Form 4
Aug 14	Andrew Booth Chief Financial Officer	Bought	37,200	$10.32	384K	6.5%	Form 4
Aug 12	Michael R Hayden Director	Bought	46,387	$10.37	481K	3.3%	Form 4
May 14	John S. Montalbano Director	Bought	20,000	$4.77	95K	8.8%	Form 4
Feb 27	Thermopylae Holdings Ltd. Large holder	Bought	38,000	$3.44	131K	<0.1%	Form 4
Feb 27	Andrew Booth Chief Financial Officer	Bought	42,600	$3.42	146K	15%	Form 4
Feb 26	Thermopylae Holdings Ltd. Large holder	Bought	177,457	$3.27	580K	0.3%	Form 4
Nov 26, 2025	John S. Montalbano Director	Bought	50,000	$3.57	179K	28%	Form 4
Mar 11, 2025	Thermopylae Holdings Ltd. Large holder	Bought	343,631	$2.16	742K	0.6%	Form 4
Mar 10, 2025	John S. Montalbano Director	Bought	25,000	$2.30	58K	17%	Form 4
Mar 6, 2025	John S. Montalbano Director	Bought	60,000	$2.34	140K	66%	Form 4

Aug 24
Michael R Hayden
Director · bought 53,613 at $10.64
570K
3.7% of stake
Aug 18
John S. Montalbano
Director · bought 10,000 at $11.03
110K
4.1% of stake
Aug 14
Andrew Booth
Chief Financial Officer · bought 37,200 at $10.32
384K
6.5% of stake
Aug 12
Michael R Hayden
Director · bought 46,387 at $10.37
481K
3.3% of stake
May 14
John S. Montalbano
Director · bought 20,000 at $4.77
95K
8.8% of stake
Feb 27
Thermopylae Holdings Ltd.
Large holder · bought 38,000 at $3.44
131K
<0.1% of stake
Feb 27
Andrew Booth
Chief Financial Officer · bought 42,600 at $3.42
146K
15% of stake
Feb 26
Thermopylae Holdings Ltd.
Large holder · bought 177,457 at $3.27
580K
0.3% of stake
Nov 26, 2025
John S. Montalbano
Director · bought 50,000 at $3.57
179K
28% of stake
Mar 11, 2025
Thermopylae Holdings Ltd.
Large holder · bought 343,631 at $2.16
742K
0.6% of stake
Mar 10, 2025
John S. Montalbano
Director · bought 25,000 at $2.30
58K
17% of stake
Mar 6, 2025
John S. Montalbano
Director · bought 60,000 at $2.34
140K
66% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ABCL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ABCL

CompareIntrinsic value

ENTAEnanta Pharmaceuticals Inc.

$10.65+2.70%25

DERMJourney Medical Corp

$4.73+1.94%25

XLOXilio Therapeutics, Inc.

$8.71+0.35%40

FBIOFortress Biotech Inc.

$1.97+1.55%59

RMTIRockwell Medical, Inc.

$8.05-0.49%37

LXRXLexicon Pharmaceuticals, Inc.

$1.48+1.37%40

VRDNViridian Therapeutics Inc.

$29.06+15.53%40

BCYCBicycle Therapeutics PLC

$3.72+1.36%40

Held by ETFs

ABCL is in 10 US ETFs. The largest of them, with ABCL's weight in each:

Spot a number that looks wrong? Check it in ABCL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ABCL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.